- Kits and reagents
- Viral inactivation systems
- Services
- Accessories
Viral Inactivation Market size was valued at USD 2.1 billion in 2022 and is poised to grow at a CAGR of 12.8% from 2023-2029. Viral inactivation is a viral removal process in which the viruses may persist in the final product but in an ineffective arrangement. Viral inactivation is a vital part of the viral clearing process and is used for all categories of pharmaceutical drugs. As a result, the market for Viral Inactivation is given a chance to expand due to the growing acceptance of the Viral Inactivation Process.
Additionally, the market is anticipated to rise as more healthcare facilities start to offer a virus-clearing process. Viral Inactivation process acceptance, medical professionals' choice of advanced products, rising healthcare costs, and rising prevalence of chronic diseases are the principal factors boosting the global market growth. Increasing acceptance day by day with the finest pricing is a significant growth driver. With the rising incidence of diseases, medical technology advancements, and investments in R&D activities, the pharmaceutical and healthcare industries have recently undergone significant changes. Public and private sector funding in medical research for medication discovery advancements will expand the market for viral inactivation. Market growth exponentially increased during the COVID-19 pandemic due, to research related to many kinds of viruses. Somehow, after the pandemic market growth is hampered, but with further investment in the advancement of healthcare sectors, this market growth will revive soon.
Viral Inactivation Market Key Developments:
In May 2021, Pharma's Almanac launched continuous inline viral inactivation for next-generation bioprocessing.
In March 2022, Thermo Fisher Scientific launched a new non-hazardous viral inactivation medium that supports the safe collection and transport of SARS-COV-2.
Viral Inactivation Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.8%
Largest Market
Asia-Pacific
Fastest Growing Market
North America
Viral Inactivation Market Dynamics
The significant driving factor for the viral inactivation market is the increasing approvals of new drugs and instructions related to the viral safety of biologics. Also, the market for Viral Inactivation is growing due to the continuous increment of various infectious diseases and the rising application of biosimilar therapeutic treatments for many diseases. The industry's expansion is mainly related to increasing investments in pharmaceutical and biotech companies and rising demand for various vaccines and biotherapy agents. However, the market is constrained by the high cost associated with technology for virus clearing methods.
North-America Got Significant Share
Viral Inactivation Market Regional Analysis
The Viral Inactivation market in North America is likely to hold a significant revenue share in 2021 and in the following years, it is predicted to increase rapidly. North America is expected for a significant share of the viral inactivation business. This can be attributed to the robust healthcare infrastructure and the presence of great pharmaceutical and biopharmaceutical companies. The increasing healthcare research and development (R&D) expenditure by the United States government is expected to fuel the market in North America. The remarkable growth of the pharmaceutical industry, increasing approvals of novel drugs, and the rising penetration of research and academic institutes that encourage biotechnology and life science research activities are projected to enhance the growth of the viral inactivation industry. Furthermore, the increasing use of technologically advanced processes for producing new and novel drugs is anticipated to boost the market growth of viral inactivation in the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The viral inactivation market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Viral Inactivation Market Segmentation
By Product Type
By Application
- Blood & blood products
- Tissue & tissue products
- Vaccines and therapeutic
- Cellular & gene therapy products
- Stem cell products
- Others
By End User
- Pharmaceutical and biotechnology companies
- Contract research organizations
- Academic research institutes
- Others
Frequently Asked Questions
The viral inactivation market is projected to expand at a CAGR of 12.8% during the forecast period
Parker Hannifin (U.S.), Clean Cells (France), Sartorius AG (Germany), Danaher Corporation (U.S.), Merck KGaA (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France)
North America is the fastest-growing region for viral inactivation market
| 1. Executive Summary |
| 2. Global Viral Inactivation Market Introduction |
| 2.1. Global Viral Inactivation Market Taxonomy |
| 2.2. Global Viral Inactivation Market Definitions |
| 2.2.1. Product Type |
| 2.2.2. Method Type |
| 2.2.3. Application |
| 2.2.4. End User |
| 2.2.5. Geography |
| 3. Global Viral Inactivation Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Viral Inactivation Market Dynamic Factors - Impact Analysis |
| 3.6. Global Viral Inactivation Market Competition Landscape |
| 4. Global Viral Inactivation Market Analysis,2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Viral Inactivation Market, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Kits, & Reagents |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Viral Inactivation Systems |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Services |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Accessories |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Viral Inactivation Market, By Method Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Pasteurization |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Solvent Detergents |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Viral Inactivation Market Forecast, By Application, 2018 - 2022and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Blood & Blood Products |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Tissue & tissue Products |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Stem Cell Products |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Cellular & gene therapy Products |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Vaccines & therapeutic |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Others |
| 7.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 8. Global Viral Inactivation Market Forecast, By End User, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. Pharmaceutical and biotechnology companies |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Contract research organizations |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Academic research institutes |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Others |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Viral Inactivation Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, End User and Region, 2023 - 2029 |
| 10. North America Viral Inactivation Market Analysis,2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 10.1. Product Type Analysis 2018 - 2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Viral inactivation systems |
| 10.1.2. Services |
| 10.1.3. Kits and reagents |
| 10.1.4. Accessories |
| 10.2. Method Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Pasteurization |
| 10.2.2. Solvent Detergents |
| 10.2.3. Others |
| 10.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Blood & blood products |
| 10.3.2. Tissue & tissue products |
| 10.3.3. Vaccines and therapeutic |
| 10.3.4. Cellular & gene therapy products |
| 10.3.5. Stem cell products |
| 10.3.6. Others |
| 10.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Pharmaceutical and biotechnology companies |
| 10.4.2. Contract research organizations |
| 10.4.3. Academic research institutes |
| 10.4.4. Others |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. USA |
| 10.5.2. Canada |
| 10.6. North America Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, End User and Country, 2023 - 2029 |
| 10.7. North America Viral Inactivation Market Dynamics Trends |
| 11. Europe Viral Inactivation Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Product Type Analysis 2018 - 2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Viral inactivation systems |
| 11.1.2. Services |
| 11.1.3. Kits and reagents |
| 11.1.4. Accessories |
| 11.2. Method Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Pasteurization |
| 11.2.2. Solvent Detergents |
| 11.2.3. Others |
| 11.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Blood & blood products |
| 11.3.2. Tissue & tissue products |
| 11.3.3. Vaccines and therapeutic |
| 11.3.4. Cellular & gene therapy products |
| 11.3.5. Stem cell products |
| 11.3.6. Others |
| 11.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Pharmaceutical and biotechnology companies |
| 11.4.2. Contract research organizations |
| 11.4.3. Academic research institutes |
| 11.4.4. Others |
| 11.5. Country Analysis 2018 - 2022and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Spain |
| 11.5.5. Italy |
| 11.5.6. Russia |
| 11.5.7. Poland |
| 11.5.8. Rest of Europe |
| 11.6. Europe Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, End User and Country, 2023 - 2029 |
| 11.7. Europe Viral Inactivation Market Dynamics Trends |
| 12. Asia-Pacific Viral Inactivation Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Product Type Analysis 2018 - 2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Viral inactivation systems |
| 12.1.2. Services |
| 12.1.3. Kits and reagents |
| 12.1.4. Accessories |
| 12.2. Method Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Pasteurization |
| 12.2.2. Solvent Detergents |
| 12.2.3. Others |
| 12.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Blood & blood products |
| 12.3.2. Tissue & tissue products |
| 12.3.3. Vaccines and therapeutic |
| 12.3.4. Cellular & gene therapy products |
| 12.3.5. Stem cell products |
| 12.3.6. Others |
| 12.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Pharmaceutical and biotechnology companies |
| 12.4.2. Contract research organizations |
| 12.4.3. Academic research institutes |
| 12.4.4. Others |
| 12.5. Country Analysis2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Japan |
| 12.5.2. China |
| 12.5.3. India |
| 12.5.4. ASEAN |
| 12.5.5. Australia & New Zealand |
| 12.5.6. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, End User and Country,2023 - 2029 |
| 12.7. Asia-Pacific Viral Inactivation Market Dynamics Trends |
| 13. Latin America Viral Inactivation Market Analysis 2018 - 2022 and Forecast, 2023 - 2029(Revenue, USD Mn) |
| 13.1. Product Type Analysis 2018 - 2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Viral inactivation systems |
| 13.1.2. Services |
| 13.1.3. Kits and reagents |
| 13.1.4. Accessories |
| 13.2. Method Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Pasteurization |
| 13.2.2. Solvent Detergents |
| 13.2.3. Others |
| 13.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Blood & blood products |
| 13.3.2. Tissue & tissue products |
| 13.3.3. Vaccines and therapeutic |
| 13.3.4. Cellular & gene therapy products |
| 13.3.5. Stem cell products |
| 13.3.6. Others |
| 13.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Pharmaceutical and biotechnology companies |
| 13.4.2. Contract research organizations |
| 13.4.3. Academic research institutes |
| 13.4.4. Others |
| 13.5. Country Analysis 2018 - 2022and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Argentina |
| 13.5.4. Rest of Latin America |
| 13.6. Latin America Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, Disease Type, End User and Country, 2023 - 2029 |
| 13.7. Latin America Viral Inactivation Market Dynamics Trends |
| 14. Middle East and Africa Viral Inactivation Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 14.1. Product Type Analysis 2018 - 2022and Forecast 2023 - 2029by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Viral inactivation systems |
| 14.1.2. Services |
| 14.1.3. Kits and reagents |
| 14.1.4. Accessories |
| 14.2. Method Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Pasteurization |
| 14.2.2. Solvent Detergents |
| 14.2.3. Others |
| 14.3. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Blood & blood products |
| 14.3.2. Tissue & tissue products |
| 14.3.3. Vaccines and therapeutic |
| 14.3.4. Cellular & gene therapy products |
| 14.3.5. Stem cell products |
| 14.3.6. Others |
| 14.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Pharmaceutical and biotechnology companies |
| 14.4.2. Contract research organizations |
| 14.4.3. Academic research institutes |
| 14.4.4. Others |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Gulf Cooperation Council (GCC) Countries |
| 14.5.2. Israel |
| 14.5.3. South Africa |
| 14.5.4. Rest of MEA |
| 14.6. MEA Viral Inactivation Market - Opportunity Analysis Index, By Product Type, Method Type, Application, Disease Type, End User and Country, 2023 - 2029 |
| 14.7. MEA Viral Inactivation Market Dynamics Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Product Type& Service Testing Types, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Parker Hannifin (U.S.) |
| 15.2.2. Clean Cells (France) |
| 15.2.3. Charles River Laboratories International, Inc. (U.S.) |
| 15.2.4. Sartorius AG (Germany) |
| 15.2.5. Danaher Corporation (U.S.) |
| 15.2.6. Merck KGaA (Germany) |
| 15.2.7. SGS S.A. (Switzerland) |
| 15.2.8. Texcell, Inc. (France) |
| 15.2.9. Viral Inactivated Plasma Systems SA (Switzerland) |
| 15.2.10. WuXi PharmaTech (Cayman) Inc. (China) |
| 15.2.11. Rad Source Technologies (U.S.) |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Parker Hannifin (U.S.)
- Clean Cells (France)
- Charles River Laboratories International, Inc. (U.S.)
- Sartorius AG (Germany)
- Danaher Corporation (U.S.)
- Merck KGaA (Germany)
- SGS S.A. (Switzerland)
- Texcell, Inc. (France)
- Viral Inactivated Plasma Systems SA (Switzerland)
- WuXi PharmaTech (Cayman) Inc. (China)
- Rad Source Technologies (U.S.)